JP2022531591A5 - - Google Patents

Info

Publication number
JP2022531591A5
JP2022531591A5 JP2021564913A JP2021564913A JP2022531591A5 JP 2022531591 A5 JP2022531591 A5 JP 2022531591A5 JP 2021564913 A JP2021564913 A JP 2021564913A JP 2021564913 A JP2021564913 A JP 2021564913A JP 2022531591 A5 JP2022531591 A5 JP 2022531591A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
pharmaceutical product
acid sequence
product according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021564913A
Other languages
English (en)
Japanese (ja)
Other versions
JP7595028B2 (ja
JP2022531591A (ja
Filing date
Publication date
Priority claimed from GBGB1906291.8A external-priority patent/GB201906291D0/en
Priority claimed from GBGB2001013.8A external-priority patent/GB202001013D0/en
Priority claimed from GBGB2001896.6A external-priority patent/GB202001896D0/en
Priority claimed from GBGB2002030.1A external-priority patent/GB202002030D0/en
Application filed filed Critical
Priority claimed from PCT/EP2020/062193 external-priority patent/WO2020225147A1/en
Publication of JP2022531591A publication Critical patent/JP2022531591A/ja
Publication of JP2022531591A5 publication Critical patent/JP2022531591A5/ja
Application granted granted Critical
Publication of JP7595028B2 publication Critical patent/JP7595028B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021564913A 2019-05-03 2020-05-01 代謝性疾患の治療および予防 Active JP7595028B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GBGB1906291.8A GB201906291D0 (en) 2019-05-03 2019-05-03 Treatment and prevention of metabolic diseases
GB1906291.8 2019-05-03
GBGB1906597.8A GB201906597D0 (en) 2019-05-03 2019-05-10 Treatment and prevention of metabolic diseases
GB1906597.8 2019-05-10
GBGB2001013.8A GB202001013D0 (en) 2020-01-24 2020-01-24 Treatment and prevention of metabolic diseases
GB2001013.8 2020-01-24
GBGB2001896.6A GB202001896D0 (en) 2020-02-12 2020-02-12 Treatment and prevention of metabolic diseases
GB2001896.6 2020-02-12
GB2002030.1 2020-02-14
GBGB2002030.1A GB202002030D0 (en) 2020-02-14 2020-02-14 Treatment and prevention of metabolic diseases
PCT/EP2020/062193 WO2020225147A1 (en) 2019-05-03 2020-05-01 Treatment and prevention of metabolic diseases

Publications (3)

Publication Number Publication Date
JP2022531591A JP2022531591A (ja) 2022-07-07
JP2022531591A5 true JP2022531591A5 (cg-RX-API-DMAC7.html) 2023-05-09
JP7595028B2 JP7595028B2 (ja) 2024-12-06

Family

ID=73051262

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021564913A Active JP7595028B2 (ja) 2019-05-03 2020-05-01 代謝性疾患の治療および予防

Country Status (13)

Country Link
US (2) US11813311B2 (cg-RX-API-DMAC7.html)
EP (1) EP3962936A1 (cg-RX-API-DMAC7.html)
JP (1) JP7595028B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220050087A (cg-RX-API-DMAC7.html)
CN (1) CN114364693A (cg-RX-API-DMAC7.html)
AU (1) AU2020268619B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021021921A2 (cg-RX-API-DMAC7.html)
CA (1) CA3146344A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002878A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021013356A (cg-RX-API-DMAC7.html)
PH (1) PH12021552763A1 (cg-RX-API-DMAC7.html)
TW (1) TW202108606A (cg-RX-API-DMAC7.html)
WO (1) WO2020225147A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220050087A (ko) * 2019-05-03 2022-04-22 싱가포르 헬스 서비시즈 피티이 엘티디 대사성 질환의 치료 및 예방
EP4110317B1 (en) 2020-02-28 2025-11-19 Praxis Precision Medicines, Inc. Kcnt1 inhibitors and methods of use
WO2021251903A1 (en) * 2020-06-09 2021-12-16 Temasek Life Sciences Laboratory Limited Automated disease detection system
CN113041248A (zh) * 2021-04-26 2021-06-29 北京亿药科技有限公司 Ravoxertinib在制备预防和/或治疗非酒精性脂肪性肝病或肝炎药物中的应用
WO2023006765A1 (en) * 2021-07-26 2023-02-02 Boehringer Ingelheim International Gmbh Treatment and prevention of alcoholic liver disease
JP2024532620A (ja) * 2021-08-30 2024-09-05 ラッセン・セラピューティクス1・インコーポレイテッド 抗IL-11Rα抗体
CN114081882B (zh) * 2021-11-15 2023-01-10 中国科学院深圳先进技术研究院 一种a-fabp蛋白抑制剂及其应用
GB202218388D0 (en) 2022-12-07 2023-01-18 Vvb Bio Pte Ltd GP130 antigen-binding molecules
EP4702047A1 (en) 2023-04-25 2026-03-04 VVB Bio Pte. Ltd. Anti il-11 antibody
WO2024259282A2 (en) * 2023-06-15 2024-12-19 The Board Of Trustees Of The Leland Stanford Junior University Interleukin 11 polypeptides and methods of use
GB202311050D0 (en) 2023-07-19 2023-08-30 Vvb Bio Pte Ltd GP130 antigen-binding molecules
GB202405551D0 (en) 2024-04-19 2024-06-05 Vvb Bio Pte Ltd Combination treatment
GB202408044D0 (en) 2024-06-06 2024-07-24 Vvb Bio Pte Ltd gp130 antigen-binding molecules
WO2026159121A1 (en) 2025-01-22 2026-07-30 VVB Bio Pte. Ltd. Bispecific molecules

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
ES2093562B1 (es) 1995-05-26 1997-07-01 Univ Santiago Compostela Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
US6649192B2 (en) 1996-07-29 2003-11-18 Universidade De Santiago De Compostela Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CA2237915A1 (en) 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
EP1311277A4 (en) 2000-07-18 2004-08-25 Joslin Diabetes Center Inc METHODS OF FIBROSIS MODULATION
AU2002362088A1 (en) * 2001-12-06 2003-06-23 Catholic University Method and composition for inducing weight loss
US8182814B2 (en) 2007-10-26 2012-05-22 Csl Limited Methods of treating inflammatory airway conditions by inhibition of IL-11 activity
CA2703544C (en) 2007-10-26 2016-01-05 Manuel Baca Cytokine muteins
US8518888B2 (en) 2008-10-14 2013-08-27 Csl Limited Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R
CN105859889B (zh) * 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
PT2953971T (pt) * 2013-02-07 2023-05-02 Csl Ltd Proteínas de ligação à il-11r e suas utilizações
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
WO2016025313A1 (en) 2014-08-11 2016-02-18 Samir Patel Methods for treating or preventing ophthalmological conditions
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
WO2017141032A1 (en) 2016-02-15 2017-08-24 Oxford University Innovation Limited Treatment of fibrotic disorders
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
US20180186871A1 (en) 2016-12-16 2018-07-05 Singapore Health Services Pte Ltd. Il-11 antibodies
GB201621431D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore The Decoy cytokine receptor
GB201806918D0 (en) 2018-04-27 2018-06-13 Enleofen Bio Pte Ltd Combination treatment for eye fibrosis
GB201809699D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
GB201809700D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
KR20220050087A (ko) * 2019-05-03 2022-04-22 싱가포르 헬스 서비시즈 피티이 엘티디 대사성 질환의 치료 및 예방

Similar Documents

Publication Publication Date Title
JP2022521591A5 (cg-RX-API-DMAC7.html)
Amet et al. Human growth hormone–transferrin fusion protein for oral delivery in hypophysectomized rats
Carteron Cytokines in rheumatoid arthritis: trials and tribulations
US20130078216A1 (en) Liver targeting molecules
JP2010500360A5 (cg-RX-API-DMAC7.html)
KR20110031373A (ko) 마크로분자 전달을 증강하는 방법 및 조성물
Ubah et al. Novel, anti-hTNF-α variable new antigen receptor formats with enhanced neutralizing potency and multifunctionality, generated for therapeutic development
BRPI1013341B1 (pt) Variantes de domínio variável único de imunoglobulina anti-albumina de soro, ligante multiespecífico e composição que compreendem as ditas variantes, bem como ácidos nucleicos e vetor
JP2019526528A5 (cg-RX-API-DMAC7.html)
JP2021505611A5 (cg-RX-API-DMAC7.html)
EP2999484A1 (en) Anti-ccl2 and anti-loxl2 combination therapy for treatment of scleroderma
TW201429988A (zh) 介白素-6抗體及其用途
JP6918005B2 (ja) 細胞内抗原に対して向けられた単一ドメイン抗体
JP2025532651A (ja) 肥満、糖尿病および肝機能障害を処置する方法
CN117003876A (zh) 一种Anti-CXCR4膜蛋白抗体及其制备方法和应用
JP2025513593A5 (cg-RX-API-DMAC7.html)
JP2023538518A5 (cg-RX-API-DMAC7.html)
TW202332691A (zh) Ige調節的疾病的治療
JP2025500288A5 (cg-RX-API-DMAC7.html)
CN115551542A (zh) 抗il-33抗体的配制品
CN113316587A (zh) 一种双特异性分子及其制备与用途
JP2024526944A5 (cg-RX-API-DMAC7.html)
EP2807191B1 (en) Methods of treating pain by inhibition of vgf activity
CN115666643A (zh) 用于治疗异位性皮肤炎的抗il-36r抗体
WO2022109022A1 (en) Rna-targeting splicing modifiers for treatment of mda5-associated conditions and diseases